Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Regeneron Pharmaceuticals · 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
nonalcoholic fatty liver disease (nafld), nonalcoholic steatohepatitis (nash), genetic risk factor, homozygous, heterozygous, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 829266
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.